Inventor · disambiguated record
Alan J. Korman
Also filed as: KORMAN ALAN · KORMAN ALAN J
88 granted patents·53 pending applications·8,171 citations·filing 1999–2025
99Inventor score
Files withBRISTOL MYERS SQUIBB CO69SQUIBB & SONS LLC33MEDAREX INC11FIVE PRIME THERAPEUTICS INC8KORMAN ALAN J4
Top patents by PatentIndex Score
141 records- 0199US10441655B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2016·Granted Oct 15, 2019·25 cites·22 claims
- 0299US9580507B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2016·Granted Feb 28, 2017·129 cites·30 claims
- 0399US9492539B2Monoclonal antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·119 cites·65 claims
- 0499US9492540B2Methods for treating cancer using anti-PD-1 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·139 cites·79 claims
- 0599US9387247B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Jul 12, 2016·124 cites·45 claims
- 0699US9358289B2Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Jun 7, 2016·137 cites·49 claims
- 0799US9273135B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Mar 1, 2016·109 cites·30 claims
- 0899US9102725B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2013·Granted Aug 11, 2015·120 cites·31 claims
- 0999US8383796B2Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2011·Granted Feb 26, 2013·355 cites·31 claims
- 1099US8017114B2Human CTLA-4 antibodies and their usesMEDAREX INC·Filed 2009·Granted Sep 13, 2011·199 cites·33 claims
- 1199US8008449B2Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeuticsMEDAREX INC·Filed 2006·Granted Aug 30, 2011·2.2k cites·23 claims
- 1299US7943743B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)MEDAREX INC·Filed 2006·Granted May 17, 2011·1.5k cites·26 claims
- 1399US7605238B2Human CTLA-4 antibodies and their usesMEDAREX INC·Filed 2001·Granted Oct 20, 2009·353 cites·32 claims
- 1499US6984720B1Human CTLA-4 antibodiesMEDAREX INC·Filed 2000·Granted Jan 10, 2006·897 cites·14 claims
- 1598US11001630B2Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted May 11, 2021·10 cites·20 claims
- 1698US10988536B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted Apr 27, 2021·10 cites·20 claims
- 1798US10344089B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2017·Granted Jul 9, 2019·25 cites·20 claims
- 1898US9580505B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Feb 28, 2017·37 cites·41 claims
- 1998US9228016B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 5, 2016·85 cites·19 claims
- 2098US9084776B2Methods for treating cancer using anti-PD-1 antibodiesMEDAREX LLC·Filed 2014·Granted Jul 21, 2015·203 cites·9 claims
- 2198US8784815B2Human CTLA-4 antibodies and their usesKORMAN ALAN J·Filed 2012·Granted Jul 22, 2014·40 cites·29 claims
- 2298US8779105B2Monoclonal antibodies to programmed death 1 (PD-1)KORMAN ALAN J·Filed 2011·Granted Jul 15, 2014·479 cites·30 claims
- 2398US8318916B2Human CTLA-4 antibodies and their usesKORMAN ALAN J·Filed 2011·Granted Nov 27, 2012·49 cites·38 claims
- 2497US11530267B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Dec 20, 2022·2 cites·21 claims
- 2597US11236165B2Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 2697US11236163B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 2797US11236164B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 2897US10501550B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 10, 2019·9 cites·58 claims
- 2997US10465010B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Nov 5, 2019·9 cites·15 claims
- 3097US10251945B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 9, 2019·20 cites·28 claims
- 3197US10196445B1Ipilimumab variant with enhanced ADCCBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Feb 5, 2019·22 cites·11 claims
- 3297US9745379B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Aug 29, 2017·11 cites·58 claims
- 3397US9605080B2Antibodies against CD73BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 28, 2017·31 cites·30 claims
- 3497US8580247B2PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereofLI BETTY·Filed 2012·Granted Nov 12, 2013·54 cites·19 claims
- 3597US8287856B2PD-1 antibodies in combination with a cytokine-secreting cell and methods of use thereofLI BETTY·Filed 2010·Granted Oct 16, 2012·80 cites·18 claims
- 3696US11512130B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Nov 29, 2022·2 cites·22 claims
- 3796US11274152B2Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 15, 2022·6 cites·12 claims
- 3896US10988535B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2019·Granted Apr 27, 2021·10 cites·20 claims
- 3996US10100129B2Antibodies against CD73 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 16, 2018·24 cites·35 claims
- 4096US8609816B2Human monoclonal antibodies to O8EKORMAN ALAN J·Filed 2006·Granted Dec 17, 2013·42 cites·26 claims
- 4196US8263073B2Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereofKORMAN ALAN·Filed 2009·Granted Sep 11, 2012·50 cites·4 claims
- 4296US7452535B2Methods of treatment using CTLA-4 antibodiesMEDAREX INC·Filed 2003·Granted Nov 18, 2008·70 cites·18 claims
- 4395US9644032B2Antibodies against OX40 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted May 9, 2017·12 cites·30 claims
- 4494US12312403B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Granted May 27, 2025·1 cites·17 claims
- 4594US11084881B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Aug 10, 2021·3 cites·19 claims
- 4694US10898556B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 26, 2021·7 cites·22 claims
- 4794US10077306B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 18, 2018·7 cites·22 claims
- 4893US11213586B2Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)BRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jan 4, 2022·5 cites·14 claims
- 4993US11207391B2Anti-ICOS agonist antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 28, 2021·4 cites·20 claims
- 5093US10533052B2Antibodies against TIM3 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jan 14, 2020·4 cites·30 claims
Showing the top 50 of 141 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Alan J. Korman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →